Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 1:23 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 6,734 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Scheduling Clear all
Completed Not applicable Interventional

Training to Reconnect With Emotional Awareness Therapy

NCT03414463
View directory record Official record
Conditions
Traumatic Brain Injury, Alexithymia
Interventions
TREAT
Behavioral
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated May 20, 2024 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Integrating Patient Generated Family Health History From Varied Electronic Health Record (EHR) Entry Portals

NCT00977847
View directory record Official record
Conditions
Family Characteristics, Health Status, Family Research
Interventions
Electronic Health Portals for collecting Family History data
Other
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
5,000 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 20, 2012 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Stage 1: Marizomib + Bevacizumab in WHO Gr IV GBM; Stage 2: Marizomib Alone; Stage 3: Combination of Marizomib and Bevacizumab

NCT02330562
View directory record Official record
Conditions
Malignant Glioma, Glioblastoma
Interventions
MRZ, BEV
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
4
States / cities
Orange, California • Santa Monica, California • New York, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2022 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Technology Based Community Health Nursing to Improve Combination Anti-Retroviral Therapy (cART) Adherence and Virologic Suppression in Youth Living With HIV

NCT03600103
View directory record Official record
Conditions
HIV Infections, Adherence, Medication
Interventions
Tech2Check
Behavioral
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years to 25 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
2
States / cities
Jacksonville, Florida • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 12, 2024 · Synced Oct 30, 2026, 1:23 PM EDT
Completed No phase listed Observational

Computational Modeling of Cleft Lip Nasal Deformity and Assessment of Nasal Function and Treatment Outcomes

NCT04150783
View directory record Official record
Conditions
Cleft Lip and Nose, Nasal Obstruction
Interventions
Surgical repair for nasal obstruction
Procedure
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2025
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 19, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Not yet recruiting Phase 2 Interventional

Semaglutide for Low Back Pain

NCT07731256
View directory record Official record
Conditions
Lower Back Pain, Obesity (BMI>30), Chronic Lower Back Pain, glp1 Agonist
Interventions
Semaglutide (administered by PDS290 pen-injector), Placebo (administered by PDS290 pen-injector)
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2031
U.S. locations
2
States / cities
Birmingham, Alabama • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional Results available

Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLL

NCT02337829
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions
Acalabrutinib (Arm A), Acalabrutinib (Arm B)
Drug
Lead sponsor
Acerta Pharma BV
Industry
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting Phase 3 Interventional

Long-term Extension of GTX-102 in Angelman Syndrome

NCT06415344
View directory record Official record
Conditions
Angelman Syndrome
Interventions
GTX-102
Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2029
U.S. locations
6
States / cities
Los Angeles, California • San Diego, California • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Eyecontrol coMmunication Platform for dEliRium manaGemEnt in Intensive Care Units (EMERGE)

NCT06029244
View directory record Official record
Conditions
Delirium, Delirium in Old Age, Critical Illness, Intensive Care Unit Delirium
Interventions
EyeControl-Pro, Control
Device · Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Dec 3, 2025 · Synced Oct 30, 2026, 1:23 PM EDT
Withdrawn Not applicable Interventional

Development and Feasibility Testing of a Mobile Phone-Based HIV Primary Care Engagement Intervention

NCT02468544
View directory record Official record
Conditions
HIV, Adherence
Interventions
Text messaging
Other
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 55 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Nov 9, 2020 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Strategies to Augment Ketosis: Ketone Conferred Resiliency Against Sleep Restriction

NCT05519644
View directory record Official record
Conditions
Sleep Deprivation
Interventions
Sleep Deprivation, Heart Rate, Sleep Monitoring, Diet, Exercise Performance, Surveys, McGill Pain Questionnaire, Shortened Profile of Mood States, Pittsburg Sleep Index, Cognitive performance, Marksmanship Performance, Quick Board, Advanced Medical Technologies Inc, Jump Test, CGM/CKM, Blood Draw, Ketone Supplement
Other · Behavioral · Biological + 1 more
Lead sponsor
Ohio State University
Other
Eligibility
18 Years to 40 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jun 1, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Voucher Based Incentives to Treat Pregnant Smokers

NCT01801384
View directory record Official record
Conditions
Efficacy of Financial Incentives
Interventions
Voucher-based incentives
Behavioral
Lead sponsor
University of Vermont
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Burlington, Vermont
Source: ClinicalTrials.gov public record
Updated May 12, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Tolerability Study of Azilsartan Medoxomil in Participants With Essential Hypertension

NCT00696384
View directory record Official record
Conditions
Hypertension
Interventions
Azilsartan medoxomil, Azilsartan medoxomil, with or without chlorthalidone and other non-angiotensin II receptor blocker antihypertensive medications., Placebo
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
33
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Jan 4, 2012 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1 Interventional

Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

NCT00731952
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
Velcade and Vorinostat
Drug
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2014
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated May 4, 2017 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Reach Home and Read

NCT03699592
View directory record Official record
Conditions
Literacy
Interventions
Reach Home and Read Toolkit
Behavioral
Lead sponsor
Duke University
Other
Eligibility
6 Months to 12 Months
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2019
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Oct 21, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

First-line Everolimus +/- Paclitaxel for Cisplatin-ineligible Patients With Advanced Urothelial Carcinoma

NCT01215136
View directory record Official record
Conditions
Transitional Cell Carcinoma, Bladder Carcinoma, Urothelial Carcinoma
Interventions
Everolimus, Paclitaxel
Drug
Lead sponsor
Matthew Galsky
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Chicago, Illinois • Bloomington, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional

Lintuzumab-Ac225 in Older Acute Myeloid Leukemia (AML) Patients

NCT02575963
View directory record Official record
Conditions
AML
Interventions
Cytarabine (Phase 1 only), Lintuzumab-Ac225, Furosemide (Phase 1 only), Spironolactone
Drug · Biological
Lead sponsor
Actinium Pharmaceuticals
Industry
Eligibility
60 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2020
U.S. locations
16
States / cities
Los Angeles, California • Lexington, Kentucky • Louisville, Kentucky + 10 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2023 · Synced Oct 30, 2026, 1:23 PM EDT
Terminated Phase 2 Interventional Results available

COVID-19 Booster Vaccine in Autoimmune Disease Non-Responders

NCT05000216
View directory record Official record
Conditions
Rheumatoid Arthritis (RA), Systemic Lupus Erythematosus (SLE), Pemphigus Vulgaris, Multiple Sclerosis (MS), Systemic Sclerosis (SSc), Pediatric SLE, Juvenile Idiopathic Arthritis (JIA), Juvenile Dermatomyositis (JDM), Pediatric-Onset Multiple Sclerosis (POMS)
Interventions
Moderna mRNA-1273, BNT162b2, Ad26.COV2.S, Continue IS (MMF or MPA), Continue IS (MTX), Continue IS (B cell depletion therapy), Monovalent [B.1.351] CoV2 preS dTM-AS03, Withhold IS (MMF or MPA), Withhold IS (MTX), Withhold IS (B cell depletion therapy), Moderna mRNA-1273, Bivalent, BNT162b2, Bivalent
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
2 Years and older
Enrollment
258 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
29
States / cities
Los Angeles, California • New Haven, Connecticut • Atlanta, Georgia + 18 more
Source: ClinicalTrials.gov public record
Updated Jun 10, 2026 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 2 Interventional

Phase 2 Study Comparing Two Dose Schedules of Telintra™ in Myelodysplastic Syndrome (MDS)

NCT00700206
View directory record Official record
Conditions
Myelodysplastic Syndrome (MDS)
Interventions
Ezatiostat Hydrochloride
Drug
Lead sponsor
Telik
Industry
Eligibility
18 Years and older
Enrollment
86 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
36
States / cities
Tucson, Arizona • Alhambra, California • Fullerton, California + 30 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2011 · Synced Oct 30, 2026, 1:23 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

A Validation Study of the NightOwl Home Sleep Apnea Test

NCT04764734
View directory record Official record
Conditions
Sleep Apnea
Interventions
NightOwl
Device
Lead sponsor
Ectosense NV
Industry
Eligibility
13 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
4
States / cities
Coral Springs, Florida • Hollywood, Florida • Miami Lakes, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 6, 2022 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Telephone Intervention for Pain Study (TIPS)

NCT00663663
View directory record Official record
Conditions
Chronic Pain, Multiple Sclerosis, Amputation, Spinal Cord Injury
Interventions
Telephone-Delivered Intervention 1, Telephone-Delivered Intervention 2
Behavioral
Lead sponsor
University of Washington
Other
Eligibility
18 Years and older
Enrollment
207 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Aug 30, 2013 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Not applicable Interventional

Post-Operative Outcomes of Low Thermal Dissection vs. Traditional Electrosurgery

NCT03711916
View directory record Official record
Conditions
Breast Cancer, Mastectomy, Perfusion; Complications, Hemostasis
Interventions
PlasmaBlade 3.0S
Device
Lead sponsor
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Other
Eligibility
18 Years to 75 Years · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 18, 2019 · Synced Oct 30, 2026, 1:23 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Aerosolized Surfactant in Neonatal RDS

NCT02294630
View directory record Official record
Conditions
Respiratory Distress Syndrome, Newborn
Interventions
Surfactant
Drug
Lead sponsor
Sood, Beena G., MD, MS
Individual
Eligibility
Up to 24 Hours
Enrollment
159 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 25, 2021 · Synced Oct 30, 2026, 1:23 PM EDT
Active, not recruiting Phase 3 Interventional Results available

Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)

NCT03553836
View directory record Official record
Conditions
Melanoma
Interventions
Pembrolizumab, Placebo
Biological · Other
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
12 Years and older
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2033
U.S. locations
39
States / cities
Tucson, Arizona • La Jolla, California • Los Angeles, California + 28 more
Source: ClinicalTrials.gov public record
Updated Nov 29, 2024 · Synced Oct 30, 2026, 1:23 PM EDT